1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Phospholipase

Phospholipase

Phospholipase is a member of a very complex group of enzymes that break down phospholipids into fatty acids and other compounds. Phospholipases are defined by the enzymatic reaction they catalyze. The classes are phospholipase A, which has members A1 and A2; phospholipase B, which can carry out the reactions of both A1 and A2; phospholipase C; and phospholipase D.

Phospholipase A2 (PLA2) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Phospholipase C (PLC) converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG and IP3 each control diverse cellular processes and are also substrates for synthesis of other important signaling molecules. PLC is thus central to many important interlocking regulatory networks. Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W012595A
    trans-Benzylideneacetone
    Inhibitor 99.87%
    trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against phospholipase A2 (PLA2). trans-Benzylideneacetone is an immunosuppressant.
    trans-Benzylideneacetone
  • HY-153559
    Lp-PLA2-IN-13
    Inhibitor
    Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases.
    Lp-PLA2-IN-13
  • HY-B0470R
    Neomycin sulfate (Standard)
    Inhibitor
    Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis.
    Neomycin sulfate (Standard)
  • HY-W019838S
    D-Erythro-dihydrosphingosine-d7
    Inhibitor 99.00%
    D-Erythro-dihydrosphingosine-d7 is the deuterium labeled D-Erythro-dihydrosphingosine. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity.
    D-Erythro-dihydrosphingosine-d<sub>7</sub>
  • HY-103097
    ST271
    Inhibitor 98.00%
    ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
    ST271
  • HY-118994
    ARN19874
    Inhibitor 99.54%
    ARN19874 is a selective, reversible uncompetitive N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) activity inhibitor with an IC50 of ~34 μM.
    ARN19874
  • HY-B0113R
    Omeprazole (Standard)
    Inhibitor
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole (Standard)
  • HY-156800
    PDDC
    Inhibitor 99.97%
    PDDC is a compound used to inhibit Alzheimer's disease. It is a nSMase2 inhibitor that can inhibit tau-induced nSMase2 activity and ceramide elevation, and slow the spread of tau in mouse models.
    PDDC
  • HY-19757
    Lp-PLA2-IN-1
    Inhibitor 99.18%
    Lp-PLA2-IN-1 is a potent Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research.
    Lp-PLA2-IN-1
  • HY-114095
    BML-280
    Inhibitor 99.64%
    BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research.
    BML-280
  • HY-173371
    BRI-50460
    Inhibitor 99.62%
    BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC50 of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of tau protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases.
    BRI-50460
  • HY-144636
    Atg4B-IN-2
    Inhibitor 98.03%
    Atg4B-IN-2 is a potent competitive Atg4B inhibitor with Ki value of 3.1 μM, also possesses declining PLA2 inhibitory potency, IC50s of 11 μM and 3.5 μM for Atg4B and PLA2, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition.
    Atg4B-IN-2
  • HY-107393
    LY-311727
    Inhibitor 99.0%
    LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme.
    LY-311727
  • HY-P2936
    Sphingomyelin phosphodiesterase, Streptomyces sp.
    Sphingomyelin phosphodiesterase, Streptomyces sp., a hydrolase, is involved in the sphingomyelin metabolism process. Sphingomyelin phosphodiesterase hydrolyzes the conversion of sphingomyelin to phosphocholine and ceramide. Sphingomyelin phosphodiesterase also plays an important role in cellular differentiation, various immune and inflammatory responses, and intracellular cholesterol trafficking and metabolism.
    Sphingomyelin phosphodiesterase, Streptomyces sp.
  • HY-D1584
    C12 NBD Sphingomyelin
    99.0%
    C12 NBD sphingomyelin is an active derivative of Sphingomyelin (HY-113498) that is tagged with fluorescent C12 nitrobenzoxadiazole (C12 NBD). C12 NBD sphingomyelin can be used as a sphingomyelinase substrate for studying the metabolism and transport of sphingomyelins (Ex=470 nm, Em=525 nm).
    C12 NBD Sphingomyelin
  • HY-70083
    SPK-601
    Inhibitor 98.46%
    SPK-601 (LMV-601) is an inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC). SPK-601 also can be used as an antimicrobial agent.
    SPK-601
  • HY-48917
    C10 Bisphosphonate
    Inhibitor 98.8%
    C10 Bisphosphonate is an inhibitor for acid sphingomyelinase. C10 Bisphosphonate is promising for research of inflammatory lung diseases, cystic fibrosis and atherosclerosis.
    C10 Bisphosphonate
  • HY-108609
    YM-26734
    Inhibitor 99.2%
    YM-26734 is a competitive inhibitor of secretory phospholipase A2 (PLA2) that exhibits a broad inhibitory profile to several PLA2s.
    YM-26734
  • HY-168431
    GK420
    Inhibitor
    GK420 (AVX420) is a potent inhibitor of cytosolic phospholipase A2α (cPLA2α), with the XI(50) of 0.0016. GK420 inhibits arachidonic acid release with the EC50 of 0.09 μM. GK420 plays an important role in cancer research.
    GK420
  • HY-115768A
    Compound 48/80 (trimer)
    Compound 48/80 (trimer) is a trimer of Compound 48/80 (HY-115768). Compound 48/80 is widely used in animal and tissue models as a "selective" mast cell activator.
    Compound 48/80 (trimer)
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.